Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Prognostic value of interim PET in patients with extranodal natural killer/T-cell lymphoma treated with non-anthracycline containing l-asparaginase based regimen

Sojin Kim, Hyungwoo Cho, Dok Hyun Yoon et al. Nov 03, 2025 pp. 3632-3632 10.1182/blood-2025-3632

Abstract Background Extranodal natural killer/T-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma predominantly involving the...

Maternal morbidity and predictors of adverse outcomes in pregnant women with sickle cell disease: A nationwide analysis (2022)

Priyanka Nagdev, Mythri Chittilla, Nishita Shettty Nov 03, 2025 pp. 7972-7972 10.1182/blood-2025-7972

Abstract Background: Pregnancy in women with sickle cell disease (SCD) is associated with high maternal morbidity, yet n...

Real-world chronic lymphocytic leukemia (CLL)–specific biomarker testing patterns and frontline treatment patterns in patients with CLL/small lymphocytic lymphoma (SLL)

Timothy Reynolds, William Ye, Linda Chen et al. Nov 03, 2025 pp. 8077-8077 10.1182/blood-2025-8077

Abstract Introduction: CLL/SLL is the most common leukemia in adults in the United States, with ~21,000 cases diagnosed annually. National C...

Integrating next-generation sequencing disease evaluation and PCR based CAR-T cell tracking to guide decision making in a real-world cohort of pediatric B-cell ALL patients.

Thomas Pfeiffer, Jeffrey Bednarski, Feng Gao et al. Nov 03, 2025 pp. 5123-5123 10.1182/blood-2025-5123

Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapy is an effective treatment option for relapsed/refractory pediatric B-c...

Comparative outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta-analysis

Chalothorn Wannaphut, Piyatida Chumnumsiriwath, Stefan Ciurea et al. Nov 03, 2025 pp. 2425-2425 10.1182/blood-2025-2425

Abstract Background: Reduced-intensity conditioning (RIC) regimens with fludarabine plus melphalan (FluMel) or busulfan (FluBu) are common i...

Superficial vein thrombosis of the upper extremities: A retrospective analysis of clot progression and role of thrombophilia testing

Terrence Sun, Annette von Drygalski, Edward Libby Nov 03, 2025 pp. 4894-4894 10.1182/blood-2025-4894

Abstract Introduction: There are well-established guidelines for the treatment of lower extremity (LE) deep venous thrombosis (DVT), but gui...

Characteristics, epidemiology and outcomes of post-transplant lymphoproliferative disorders associated hospitalizations: A 2016-2022 national inpatient sample analysis

Deepika Dilip, Heng Jiang, Christopher Poletes et al. Nov 03, 2025 pp. 4422-4422 10.1182/blood-2025-4422

Abstract Introduction: Post-transplant lymphoproliferative disorders (PTLD) are rare but serious lymphoid proliferations following solid org...

Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms

John Crispino, Jeremy Wen, Anitria Cotton et al. Nov 03, 2025 pp. 67-67 10.1182/blood-2025-67

Abstract Menin inhibition has emerged as an exciting therapeutic strategy for acute myeloid leukemia associated with KMT2A-rearrangements an...

Manufacturing variability of CAR-T cells in patients with B-cell lymphoma: Findings from the carthiae-1 clinical trial

Raquel Paiva, Julia Teixeira Cottas de Azevedo, João Agostinho Machado-Neto et al. Nov 03, 2025 pp. 7701-7701 10.1182/blood-2025-7701

Abstract Background: Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a promising treatment modality for patients with relaps...

Asciminib for relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of chronic myeloid leukemia (LBC-CML) in Italy: A Campus ALL real life study

Matteo Dragani, Patrizia Chiusolo, Giulia Rivoli et al. Nov 03, 2025 pp. 1572-1572 10.1182/blood-2025-1572

Abstract Background: The introduction of tyrosine kinase inhibitors (TKIs) has markedly improved the outcome of Philadelphia positive acute...

Tfeb regulates CD8+ T-cell proliferation In Vivo

Marisa Aitken, Luis Correa-Medero, Kantaro Inoki et al. Nov 03, 2025 pp. 3005-3005 10.1182/blood-2025-3005

Abstract CD8+ T-cells are critical components of anti-viral and anti-tumor immunity. Our accumulating understanding of their function has al...

Trends in mortality due to hematological malignancies and aplastic anemia in US adults from 1999-2023: A 24-year retrospective analysis of the CDC wonder database

Eshal Saghir, Muhammad Affan, Maryam Saghir et al. Nov 03, 2025 pp. 8188-8188 10.1182/blood-2025-8188

Abstract Introduction: Hematologic malignancies have caused over 1.4 million deaths among U.S. adults between 1999 and 2020, with 185,840 ne...

Social determinants of health and outcomes in patients with acute leukemia: Interim results from a prospective, single institution study

Maire Okoniewski, Tara Lin, Jianzheng Wu et al. Nov 03, 2025 pp. 6403-6403 10.1182/blood-2025-6403

Abstract Introduction: Individual and population-based social determinants of health (SDOH) have been shown to negativel...

Efficacy of a virtual reality headset for managing severe pain during sickle cell vaso-occlusive crisis: A single-center study in adults.

Geoffrey Cheminet, Anne Corbasson, Kinda Al Kudsee et al. Nov 03, 2025 pp. 413-413 10.1182/blood-2025-413

Abstract Background: In adult patients with sickle cell disease (SCD), regular use of opioid analgesics during a vaso-occlusive crisis (VOC)...

Effectiveness and safety of polatuzumab vedotin combined with zuberitamab plus cyclophosphamide, doxorubicin and prednisone in untreated diffuse large B-cell lymphoma: A real-world study from China

Wei Li, Lanfang Li, Xianming Liu et al. Nov 03, 2025 pp. 2747-2747 10.1182/blood-2025-2747

Abstract Introduction Polatuzumab vedotin (pola) plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) d...

Engineered extracellular vesicles for In Vivo gene therapy in sickle cell disease

Michaela Bhoorasingh, Evan Vail, Yeshin Yoon et al. Nov 03, 2025 pp. 2534-2534 10.1182/blood-2025-2534

Abstract Sickle Cell Disease (SCD) is a genetic blood disorder that affects over 100,000 persons in the U.S. and 20 million people worldwide...

Shifting treatment paradigms lead to improved overall survival in Acute Myeloid Leukemia: Real-world data from an integrated health system.

Sabiha Tamima, Eric Elkin, Lisa Law et al. Nov 03, 2025 pp. 1607-1607 10.1182/blood-2025-1607

Abstract Introduction: For the past decade, treatment options for acute myeloid leukemia (AML) have evolved with the approval of hypomethyla...

Multi-faceted influence of immunomodulatory metabolites on CAR-T cell therapy

Dhyani Shah, Markus Perl, Matthias Fante et al. Nov 03, 2025 pp. 2343-2343 10.1182/blood-2025-2343

Abstract Background:Chimeric antigen receptor (CAR) T cell therapy has revolutionized treatment for hematologic malignancies achieving high...

Increasing the proportion, accessibility, and quality of individualized pain plans for adults with sickle cell disease

Rania Mohamed, Melody Hall, Shieghetha Edwards et al. Nov 03, 2025 pp. 2597-2597 10.1182/blood-2025-2597

Abstract Introduction: Sickle cell disease (SCD) is characterized by recurrent episodes of severe pain, often necessitating treatment in acu...

Pilot study on thrombosis risk factors in sickle cell anemia

Nicoy Downie, Sree Lanka, Monique Fagan et al. Nov 03, 2025 pp. 1191-1191 10.1182/blood-2025-1191

Abstract Background:Sickle cell disease (SCD) is a complex hemoglobinopathy affecting approximately 70,000–100,000 individuals in the United...

Quality of life and symptom burden in PNH: A real-world study on the impact of treatment access

Lyam Carlo Chacon Rangel, Jose Alvarez, Andrea Mirelly López Flores et al. Nov 03, 2025 pp. 6254-6254 10.1182/blood-2025-6254

Abstract Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening hematologic disorder characterized by complement...

The CML and the ALL inducing isoforms of BCR::ABL1 differ for the induction of genomic instablity

Rosemary Wilson, Kierney O'Dare, Claudia Chriches et al. Nov 03, 2025 pp. 3253-3253 10.1182/blood-2025-3253

Abstract There are two major isoforms of BCR::ABL1, the Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) specific p18...

Correction of ineffective erythropoiesis and durable clinical benefit with exagamglogene autotemcel for transfusion-dependent β-thalassemia

Franco Locatelli, Roland Meisel, Selim Corbacioglu et al. Nov 03, 2025 pp. 6089-6089 10.1182/blood-2025-6089

Abstract Background: Transfusion-dependent β-thalassemia (TDT) patients have tissue iron overload (IO) from chronic red blood cell (RBC) tra...

17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease

Gunin Singhal, Franceso Versino, Kevin Hung et al. Nov 03, 2025 pp. 3858-3858 10.1182/blood-2025-3858

Abstract Introduction: The 5th edition of the World Health Organization (WHO-5) and the International Consensus Classification (ICC) recogniz...

Spatial transcriptomics uncovers unique tumor microenvironments in folliculotropic versus classic mycosis fungoides

Madeline Williams, Daniel Joffe, Jenna Mandel et al. Nov 03, 2025 pp. 5326-5326 10.1182/blood-2025-5326

Abstract Introduction: The most common subtype of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), is characterized by proliferatio...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page